The Federation of European Biochemical Societies (FEBS) was founded in 1964 to bring together the scientific societies of Europe and neighbouring regions and to provide a platform for scientific exchange. Today, FEBS is an organisation of more than 30 000 members across 39 biochemistry and molecular biology societies that promotes excellence in the life sciences in Europe and beyond. To mark the 60 anniversary of FEBS, FEBS Letters celebrated with a writing contest focussed on participants' visions of scientific societies in the year 2084. Here, we present the winning essay, in which Yussuf Ali (Jagiellonian University, Poland) considers a future in which FEBS transcends not only geographical boundaries, but also interdisciplinary, technological and financial boundaries.

Download full-text PDF

Source
http://dx.doi.org/10.1002/1873-3468.15065DOI Listing

Publication Analysis

Top Keywords

scientific societies
12
future febs
8
febs
6
societies
5
blueprints scientific
4
scientific society
4
society future
4
scientific
4
febs scientific
4
societies will
4

Similar Publications

Introduction: The Friedreich Ataxia Rating Scale-Activities of Daily Living (FARS-ADL) is a validated and highly utilized measure for evaluating patients with Friedreich Ataxia. While construct validity of FARS-ADL has been shown for spinocerebellar ataxia (SCA), content validity has not been established.

Methods: Individuals with SCA1 or SCA3 (n = 7) and healthcare professionals (HCPs) with SCA expertise (n = 8) participated in qualitative interviews evaluating the relevance, clarity, and clinical meaningfulness of FARS-ADL for assessment of individuals with SCA.

View Article and Find Full Text PDF

Background: Research on fertility preservation among women diagnosed with lymphoma is very limited. We aimed to assess the receipt of fertility preservation information and use of fertility preservation among women diagnosed with lymphoma.

Methods: This was a retrospective, single-centre study.

View Article and Find Full Text PDF

Standard: Human gastric organoids.

Cell Regen

January 2025

Guangzhou National Laboratory, Guangzhou, 510005, China.

Organoid technology provides a transformative approach to understand human physiology and pathology, offering valuable insights for scientific research and therapeutic development. Human gastric organoids, in particular, have gained significant interest for applications in disease modeling, drug discovery, and studies of tissue regeneration and homeostasis. However, the lack of standardized quality control has limited their extensive clinical applications.

View Article and Find Full Text PDF

The history of the Czech and Slovak experimental cardiology describes a completely unusual curve. The personality of J.E.

View Article and Find Full Text PDF

Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS.

J Bone Oncol

February 2025

Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.

Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!